
Psychedelic Business Spotlight: July 16, 2021
Business, Stock Reports
This week in psychedelic business news: A generous donation to advance MDMA research, psilocybin for end-of-life anxiety, and provisional patents filed for synthesizing ibogaine.
What irony: Dr. Markus Roggen had to retract two articles (of the 3 he published) because he manipulated data, which amounts to scientific misconduct.
Please see:
https://pubs.acs.org/doi/10.1021/ja412119q
and
https://onlinelibrary.wiley.com/doi/10.1002/anie.201309901
Willful data manipulation to remove evidence of impurities would constitute an ethical breach and is seen as such by peers in the field of chemistry as you must be aware.
It is highly ironic that Dr. Roggen would now be running CBDV-Delic Labs, an analytical testing company where adherence to standards for data presentation would be paramount in order to address issues of purity and detect various analytes in extracts etc. Why anyone would invest in DELIC is puzzling to say the least.